齐鲁制药上海临床研究中心 Mediaroom

Updated Data from Phase II Clinical Trial of Iruplinalkib Tablets (Qixinke®) Presented at World Conference on Lung Cancer 2024

JINAN, China, Sept. 10, 2024 /PRNewswire/ -- During the World Conference on Lung Cancer (WCLC) held...

2024-09-10 18:00 1003

Qilu Pharmaceutical's Three Clinical Studies on Cancer Immunotherapy Presented at ASCO 2024

JINAN, China, June 6, 2024 /PRNewswire/ -- The 2024 American Society of Clinical Oncology (ASCO) An...

2024-06-07 14:51 1609

Qilu Pharmaceutical's Three Clinical Studies on Cancer Immunotherapy Presented at ASCO 2024

Qilu Pharmaceutical Showcases QL1706 Clinical Trial Outcomes in Oral Presentation at ESGO 2024

JINAN, China, March 15, 2024 /PRNewswire/ -- On 8 March local time, during the 25th European Societ...

2024-03-15 14:07 2643

Results from the Clinical Trial of Qilu Pharmaceutical's Novel Anticancer Agent Iparomlimab and Tuvonralimab (QL1706) Featured in Oral Presentation at the ESGO Annual Meeting

JINAN, China, March 4, 2024 /PRNewswire/ -- The European Society of Gynecological Oncology (ESGO) 2...

2024-03-04 16:53 1831

Results from the Clinical Trial of Qilu Pharmaceutical's Novel Anticancer Agent Iparomlimab and Tuvonralimab (QL1706) Featured in Oral Presentation at the ESGO Annual Meeting

Results of Phase II Study on Qilu Pharmaceutical's Novel Drug QL1706 Published in Signal Transduction and Targeted Therapy

JINAN, China, Feb. 2, 2024 /PRNewswire/ -- On January 29th, the results of the phase II study on Qi...

2024-02-02 17:34 1771

Results of the Phase III INSPIRE Study on Qilu Pharmaceutical's Iruplinalkib Published in the Journal of Thoracic Oncology

JINAN, China, Jan. 30, 2024 /PRNewswire/ -- The interim analysis results from the phase III INSPIRE...

2024-01-30 16:45 1578

Qilu Pharmaceutical Announces Results from Phase I Clinical Study for Its Novel Bispecific Antibody QLS31905 at ESMO Immuno-Oncology Congress

JINAN, China, Dec. 12, 2023 /PRNewswire/ -- During the ESMO Immuno-Oncology Congress 2023 held inGe...

2023-12-12 11:04 1970

Qilu Pharmaceutical Announces Results from Phase II Study for iparomlimab for Advanced Solid Tumors at ESMO Asia, with an ORR of 45.8%

JINAN, China, Dec. 6, 2023 /PRNewswire/ -- Qilu Pharmaceutical presented the latest results of the ...

2023-12-06 16:55 2023

Phase I Study Results for Qilu Pharmaceutical's Iparomlimab (QL1604) Now Published

JINAN, China, Nov. 6, 2023 /PRNewswire/ -- Recently, the results of the Phase I study for iparomlim...

2023-11-06 18:54 1603

Qilu Pharmaceutical announces the latest results from its clinical study on QL1706, in combination with chemotherapy, as a first-line treatment for recurrent or metastatic cervical cancer

JINAN, China, Oct. 25, 2023 /PRNewswire/ -- On October 22, Qilu Pharmaceutical unveiled the latest ...

2023-10-25 22:33 2096

Qilu Pharmaceutical announces the latest results from its clinical study on QL1706, in combination with chemotherapy, as a first-line treatment for recurrent or metastatic cervical cancer

JINAN, China, Oct. 25, 2023 /PRNewswire/ -- On October 22, Qilu Pharmaceutical unveiled the latest ...

2023-10-25 22:15 1970

Qilu Pharmaceutical to Showcase Novel Anti-Cancer Drug QL1706 at ESMO Congress 2023

JINAN, China, Oct. 19, 2023 /PRNewswire/ -- Data from Qilu Pharmaceutical's clinical trial of its n...

2023-10-19 19:42 1949

QiLu Pharmaceutical's Iruplinalkib Phase III INSPIRE Study Researched Primary Endpoint and was Selected for 2023 WCLC Oral Presentation

JINAN, China, Aug. 18, 2023 /PRNewswire/ -- August 16, 2023, at the 2023 World Conference on Lung C...

2023-08-18 09:50 2479

Qilu Pharmaceutical Announces Trials in Progress Posters on QL1706 in Phase III NSCLC Clinical Research at ASCO 2023

JINAN, China, June 8, 2023 /PRNewswire/ -- Recently, Qilu Pharmaceutical presented a Trials in Prog...

2023-06-08 15:35 2375

Advances of Qilu Pharmaceutical's QL1706 in Clinical Research Presented at ASCO Annual Meeting

JINAN, China, June 1, 2023 /PRNewswire/ -- The American Society of Clinical Oncology (ASCO) recentl...

2023-06-01 00:55 2527

Results of Phase I Clinical Study of Qilu Pharma's PD-1/CTLA-4 Bifunctional Antibody Iparomlimab/Tuvonralimab Published Online in Journal of Hematology & Oncology

JINAN, China, May 12, 2023 /PRNewswire/ -- On May 8, 2023, Journal of Hematology & Oncology (JHO, 2...

2023-05-12 17:40 2167

Results of Phase I Clinical Study of Qilu Pharma's PD-1/CTLA-4 Bifunctional Antibody Iparomlimab/Tuvonralimab Published Online in Journal of Hematology & Oncology

JINAN, China, May 11, 2023 /PRNewswire/ -- On May 8, 2023, the authoritative oncology journal, Jour...

2023-05-11 20:55 2404

Qilu Pharmaceutical Announces Progress of Clinical Study of QL1706, an Innovative Bifunctional Antibody

JINAN, China, Dec. 29, 2022 /PRNewswire/ -- In 2022, Qilu Pharmaceutical revealed the latest progre...

2022-12-29 14:32 1902

Qilu Pharmaceutical Releases Latest Results of QL1604 plus Chemotherapy as First-Line Treatment for Patients with Advanced Cervical Cancer in the Phase II Study at ESMO Asia Congress 2022

JINAN, China, Dec. 4, 2022 /PRNewswire/ -- Qilu Pharmaceutical, one of the leading vertically integ...

2022-12-04 17:00 1644

Qilu Pharmaceutical Releases Latest Results of QL1706 plus Chemotherapy +/- Bevacizumab for the Treatment of Non-Small Cell Lung Cancer in the Phase II Study at ESMO Asia Congress 2022

JINAN, China, Dec. 2, 2022 /PRNewswire/ -- Qilu Pharmaceutical, one of the leading vertically integ...

2022-12-02 16:20 1497

Latest News